通过3 - 库马林衍生物的TRPA1抑制效应
Carita Sallomy1, Paul Awolade2, Minna Rahnasto-Rilla1
1School of Pharmacy, University of Eastern Finland, Kuopio 70211, Finland.
ACS medicinal chemistry letters
|August 14, 2024
概括
研究人员确定了新型3 - 库马林化合物作为暂时受体潜在安基林1 (TRPA1) 蛋白的抑制剂. 这些化合物显示出治疗疼痛和炎症的潜力,其中一种也会影响乳腺癌细胞.
科学领域:
- 药用化学 医学化学
- 药理学 药理学是指药理学的学科.
- 计算机化药物设计技术
背景情况:
- 暂时受体潜能安基林1 (TRPA1) 与炎症反应和疼痛条件有关.
- TRPA1为开发新型止痛药和抗炎药物提供了一个可行的目标.
研究的目的:
- 通过计算机辅助药物设计 (CADD) 识别和设计潜在的TRPA1抑制剂.
- 合成和评估新型3 - 库马林衍生物对TRPA1.1.的抑制活性.
- 探索这些化合物在疼痛,炎症和癌症中的潜在治疗应用.
主要方法:
- 利用计算机辅助药物设计 (CADD) 识别潜在的TRPA1结合部位和抑制剂.
- 采用微波辅助合成来创建一个3-phenylcoumarin衍生物库.
- 进行了体外测试,以评估合成化合物的TRPA1抑制活性.
主要成果:
- 成功合成了几种具有TRPA1抑制活性的基于3-甲的化合物.
- 化合物3 - 3 - 3 - 基 - 7 - 乙基 (5),7 - 基 - 3 - 3 - 基 - (12) 和3 - 3 - 3 - 基 - (23) 在体外显示出显著的TRPA1抑制.
- 化合物5通过减少乳腺癌细胞大小和形成而表现出额外的活性.
结论:
- 针对TRPA1的新型3-库马林衍生物提供了对疼痛和炎症的有前途的治疗策略.
- 这些已识别的化合物需要进一步研究它们在治疗TRPA1相关疾病,包括癌症方面的潜力.
相关概念视频
Drugs Affecting Neurotransmitter Release or Uptake
1.0K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.0K
Cholinergic Antagonists: Pharmacological Actions
1.0K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.0K
Cholinergic Antagonists: Pharmacokinetics
424
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
424
Desensitization and Tachyphylaxis
1.6K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.6K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Adrenergic Agonists: Indirect-Acting Agents
1.5K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.5K


